Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 4 sources · 5 days · First seen · Last updated
Indian pharmaceutical company financial performance
Overview
Major Indian pharmaceutical firms reported divergent financial results for the September quarter. Neuland Laboratories Limited experienced a 47 percent year-on-year decline in net profit and a 12.5 percent drop in revenue. Sun Pharmaceutical Industries also reported a 36.36 percent decrease in consolidated net profit, though its total revenue increased. The profit decline for Sun Pharmaceutical was attributed to exceptional charges, including a Rs 923 crore settlement for US generic-pricing antitrust litigation and costs related to the proposed acquisition of Organon.
In contrast, Gland Pharma reported a 58.29 percent increase in consolidated net profit, driven by strong execution and a 31 percent increase in its CDMO business. The company also launched four molecules in the US during this period.
Entities
Gland Pharma · Apollo Tyres · United States · India · Sun Pharmaceutical Industries
Timeline
-
[BUSINESS] 2 sourcesIndian companies Gland Pharma and Apollo Tyres report quarterly growth
Gland Pharma and Apollo Tyres reported strong quarterly results, with Gland Pharma seeing a 58 percent profit surge and Apollo Tyres achieving 17 percent revenue growth.
-
[BUSINESS] 3 sourcesIndian pharmaceutical companies report mixed Q2 earnings
Neuland Laboratories reported a 47 percent profit drop, while Sun Pharma saw profits fall 36 percent despite rising revenues, impacted by litigation costs and acquisition expenses.
Sources
bhaskarlive.in · indusbusinessjournal.com · medicaldialogues.in · namastecar.com